Home LiteratureArticle Details
PMID: 10993857 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Circulation ·Vol. 102 ·No. 12 ·2000-09-19 ·Pages 1388-93

Brilla CG, Funck RC, Rupp H

Abstract

In arterial hypertension, left ventricular hypertrophy (LVH) includes myocyte hypertrophy and fibrosis, which leads to LV diastolic dysfunction and, finally, heart failure. In spontaneously hypertensive rats, myocardial fibrosis was regressed and LV diastolic function was improved by treatment with the angiotensin-converting enzyme inhibitor lisinopril. Whether this holds true for patients with hypertensive heart disease was addressed in this prospective, randomized, double-blind trial. A total of 35 patients with primary hypertension, LVH, and LV diastolic dysfunction were treated with either lisinopril (n=18) or hydrochlorothiazide (HCTZ; n=17). At baseline and after 6 months, LV catheterization with endomyocardial biopsy, Doppler echocardiography with measurements of LV peak flow velocities during early filling and atrial contraction and isovolumic relaxation time, and 24-hour blood pressure monitoring were performed. Myocardial fibrosis was measured by LV collagen volume fraction and myocardial hydroxyproline concentration. With lisinopril, collagen volume fraction decreased from 6.9+/-0.6% to 6. 3+/-0.6% (P:<0.05 versus HCTZ) and myocardial hydroxyproline concentration from 9.9+/-0.3 to 8.3+/-0.4 microg/mg of LV dry weight (P:<0.00001 versus HCTZ); this was associated with an increase in the early filling and atrial contraction LV peak flow velocity ratio from 0.72+/-0.04 to 0.91+/-0.06 (P:<0.05 versus HCTZ) and a decrease in isovolumic relaxation time from 123+/-9 to 81+/-5 ms (P:<0.00002 versus HCTZ). Normalized blood pressure did not significantly change in either group. No LVH regression occurred in lisinopril-treated patients, whereas with HCTZ, myocyte diameter was reduced from 22. 1+/-0.6 to 20.7+/-0.7 microm (P:<0.01 versus lisinopril). In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function.

MeSH Terms
Adolescent Adult Aged Analysis of Variance Angiotensin-Converting Enzyme Inhibitors/therapeutic use Antihypertensive Agents/therapeutic use Blood Pressure/drug effects Cardiomyopathies/drug therapy Double-Blind Method Female Fibrosis/drug therapy Humans Hydrochlorothiazide/therapeutic use Lisinopril/therapeutic use Male Middle Aged Myocardium/pathology Prospective Studies Ventricular Dysfunction, Left/drug therapy
Chemicals
Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Hydrochlorothiazide Lisinopril
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Brilla C G
Division of Cardiology, Philipps University of Marburg, Marburg, Germany.
Funck R C
Rupp H
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
1524-4539
Published
2000-09-19
Pages
1388-93
Language
English
Region
United States
NLM ID
0147763
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com